Integrating single‑cell transcriptomics and machine‑learning model screening to identify a KIAA0408‑associated B‑cell prognostic signature in ovarian cancer
Year: 2026
Type: article
Abstract: Ovarian cancer is the most lethal gynecologic malignancy, with most patients exhibiting suboptimal responses to T cell-targeted immune checkpoint inhibitors. Despite increasing attention to B cells in tumor immunity, the role of tumor-infiltrating B cells in ovarian cancer remains incompletely elucidated. Using single-cell RNA sequencing data, we constructed a high-resolution cellular atlas of the high-grade serous ovarian cancer, integrating inferCNV, CytoTRACE, and hdWGCNA to systematically analyze B cell copy number variations, differentiation trajectories, and co-expression networks. A machine learning-derived prognostic risk model was evaluated across multiple cohorts. The immune microenvironment was computationally profiled with ESTIMATE and immune deconvolution. KIAA0408‑related phenotypes were assessed by flow cytometry, immunoblotting, cell‑cycle, colony‑formation and CCK‑8 assays. Drug candidates were screened in databases and validated experimentally. Single-cell sequencing reveals ovarian cancer B cell heterogeneity, aberrant T-cell crosstalk, and KIAA0408 as a core regulator. The model of KIAA0408, CEACAM8, CAPZA1, PTCH1 and VPS13A showed prognostic stratification, pending validation in independent cohorts. High-risk patients exhibited an “ineffective inflammation” phenotype, featuring myeloid-derived suppressor cell-predominant infiltration, insufficient memory T cells, and impaired anti-tumor immunity. Mechanistically, KIAA0408 overexpression correlated with suppressed BCR‑AKT signaling and altered B‑cell‑cycle and conditioned‑medium phenotypes. Isoliquiritigenin showed antiproliferative effects, which may be linked to modulation of this pathway. This study reveals KIAA0408-mediated B-cell immune regulation in ovarian cancer, proposes a multi-gene prognostic model pending independent validation, and identifies isoliquiritigenin as a potential therapeutic agent.
Source: Journal of Ovarian Research
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W7162789574
